How many 8-K filings has Sensei Biotherapeutics, Inc. filed?

Sensei Biotherapeutics, Inc. (SNSE) has 29 8-K (Current Event Report) filings on record, spanning Jan 2024 to Mar 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Sensei Biotherapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Sensei Biotherapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Sensei Biotherapeutics, Inc. (SNSE) — 8-K Filings

All 8-K filings from Sensei Biotherapeutics, Inc.. Browse 29 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (29)

Sensei Biotherapeutics Files 8-K on Financials — Mar 30, 2026 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial state
Sensei Biotherapeutics Announces Board and Officer Changes — Dec 23, 2025 Risk: medium
Sensei Biotherapeutics, Inc. announced on December 22, 2025, changes in its board of directors and officer appointments. Specifically, the company reported the
Sensei Biotherapeutics Files 8-K — Nov 14, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on November 14, 2025, reporting on its results of operations and financial condition. The filing includes financial st
Sensei Biotherapeutics Files 8-K — Oct 30, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on October 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details
Sensei Biotherapeutics Files 8-K — Oct 17, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on October 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Sensei Biotherapeutics Files 8-K on Financials — Aug 5, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing includes financial state
Sensei Biotherapeutics Faces Delisting Concerns — Jul 9, 2025 Risk: high
Sensei Biotherapeutics, Inc. filed an 8-K on July 9, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earli
Sensei Biotherapeutics Files 8-K for Bylaw Amendments — Jun 13, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on June 13, 2025, reporting events as of June 12, 2025. The filing primarily concerns amendments to its articles of in
Sensei Biotherapeutics Files 8-K on Shareholder Votes — May 23, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on May 23, 2025, reporting on matters submitted to a vote of security holders as of May 21, 2025. The filing details t
Sensei Biotherapeutics Files 8-K on Financials — May 6, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
Sensei Biotherapeutics Files 8-K on Financials — Mar 28, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on March 28, 2025, reporting on its results of operations and financial condition. The filing also includes financial
Sensei Biotherapeutics Files 8-K — Mar 27, 2025 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on March 27, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporat
Sensei Biotherapeutics Faces Nasdaq Delisting Warning — Jan 7, 2025 Risk: high
Sensei Biotherapeutics, Inc. filed an 8-K on January 7, 2025, to report its failure to meet Nasdaq's minimum bid price requirement. The company was notified by
Sensei Biotherapeutics Files 8-K on Financials — Nov 14, 2024 Risk: medium
Sensei Biotherapeutics, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial st
Sensei Biotherapeutics: Leadership Changes and New Board Member — Oct 30, 2024 Risk: medium
Sensei Biotherapeutics, Inc. announced on October 25, 2024, the departure of Dr. John F. McDonald as Chief Medical Officer. The company also elected Dr. Michael
Sensei Biotherapeutics Appoints New CMO and Director — Sep 20, 2024 Risk: medium
Sensei Biotherapeutics, Inc. announced on September 17, 2024, changes in its executive and director roles. Dr. John F. McDonald has been appointed as the new Ch
Sensei Biotherapeutics Files 8-K on Financials — Aug 6, 2024 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing includes financial state
Sensei Biotherapeutics Faces Nasdaq Delisting Warning — Jul 12, 2024 Risk: high
Sensei Biotherapeutics, Inc. announced on July 10, 2024, that it received a notification from the Nasdaq Stock Market indicating a failure to meet the minimum b
Sensei Biotherapeutics Adds Oncology Expert to Board — Jun 27, 2024 Risk: low
Sensei Biotherapeutics, Inc. announced on June 26, 2024, the election of Dr. Jonathan Jonathan as a new Class II director to its Board of Directors. Dr. Jonatha
Sensei Biotherapeutics Reports Shareholder Vote Matters — Jun 13, 2024 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on June 13, 2024, reporting on matters submitted to a vote of security holders on June 11, 2024. The filing details ac
Sensei Biotherapeutics Files 8-K — Jun 3, 2024 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
Intellia Therapeutics to Acquire Sensei Biotherapeutics for $300M — May 23, 2024 Risk: medium
Sensei Biotherapeutics, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Intellia Therapeutics,
Sensei Biotherapeutics Files 8-K on Financials — May 9, 2024 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
Sensei Biotherapeutics Appoints New CMO, CEO Employment Agreement — Apr 12, 2024 Risk: medium
Sensei Biotherapeutics, Inc. announced on April 11, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Robert L. Kirk was app
Sensei Biotherapeutics Appoints New CMO, Director — Apr 2, 2024 Risk: medium
Sensei Biotherapeutics, Inc. announced on March 27, 2024, the appointment of Dr. John W. Miller as Chief Medical Officer and the election of Ms. Jennifer L. Jon
Sensei Biotherapeutics Files 8-K: Material Agreements & Security Holder Rights — Mar 5, 2024 Risk: medium
On March 5, 2024, Sensei Biotherapeutics, Inc. entered into a material definitive agreement. The company also made modifications to the rights of its security h
Sensei Biotherapeutics Relocates HQ, Updates Financials — Feb 28, 2024 Risk: low
Sensei Biotherapeutics, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition. The filing also updated its busi
Sensei Biotherapeutics Reports Officer Compensation, Director Changes — Feb 8, 2024 Risk: medium
Sensei Biotherapeutics, Inc. filed an 8-K on February 8, 2024, reporting an event that occurred on February 5, 2024. This filing indicates a change in the compa
Sensei Biotherapeutics Confirms Nasdaq Listing for Common & Preferred Stock — Jan 4, 2024
Sensei Biotherapeutics, Inc. filed an 8-K on January 4, 2024, primarily to disclose that its Common Stock (SNSE) and Series A Preferred Stock Purchase Rights ar

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX